The role of death receptor 3 in the biological behavior of hepatocellular carcinoma cells

Zhang,You  Cheng; Guo,Liu  Qing; Chen,Xiao; Wang,Gen  Nian; Ni,Ri; Wang,Man  Cai; Wei,Feng  Xian

doi:10.3892/mmr.2014.2858

The role of death receptor 3 in the biological behavior of hepatocellular carcinoma cells

Authors:
- You Cheng Zhang
- Liu Qing Guo
- Xiao Chen
- Gen Nian Wang
- Ri Ni
- Man Cai Wang
- Feng Xian Wei
View Affiliations

Affiliations: Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P.R. China, Hepato‑Biliary‑Pancreatic Institute, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P.R. China
Published online on: November 4, 2014 https://doi.org/10.3892/mmr.2014.2858
Pages: 797-804
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Death receptor 3 (DR3) belongs to the tumor necrosis factor (TNF) receptor superfamily, primarily found in lymphoid tissues. Reports have determined that DR3 may also be distributed in numerous types of tumors. Therefore, it is thought that DR3 may have an important role in the process of tumorigenesis. The aim of the present study was to observe the effect of silencing DR3 expression on hepatocarcinoma cell growth, apoptosis and invasion in order to elucidate the role of DR3 in tumor development. The hepatocarcinoma cell lines (HepG2, Huh7, SMMC7721 and Bel‑7402) and normal human liver cells (HL‑7702) were transfected with three stealth RNA interference (RNAi) sequences that target the DR3 gene. Reverse transcription quantitative polymerase chain reaction was used to detect the expression levels of DR3 in hepatocarcinoma cell lines and normal liver HL‑7702 cells. MTT assay and flow cytometry (FCM) were used to determine the rates of cell proliferation and apoptosis, respectively. Following silencing of the DR3 gene, western blot analysis was used to determine the protein expression of P53, Fas, Caspase8, nuclear factor kappa‑light‑chain‑enhancer of activated B cells (NF‑κB) and Caspase3. DR3 messenger RNA (mRNA) expression in hepatocarcinoma cell lines was significantly increased compared with that in the normal liver cell line. Three targeted DR3 gene small interfering RNAs significantly inhibited DR3 gene expression in Bel‑7402 cells at the nucleic acid level. AF02670.1_stealth_883 and cocktail demonstrated the most efficient inhibition of DR3 gene expression at 48 and 72 h following transfection, with mRNA inhibition rates of 89.46 and 92.75%, and 90.53 and 94.25% (P<0.01), respectively. Cell viability was significantly reduced by AF02670.1_stealth_883 and RNAi cocktail at 24, 48 and 72 h following transfection. The inhibition rates of cell proliferation were 50.76 and 61.76% (P<0.05) at 72 h following transfection. FCM revealed that AF02670.1_stealth_883 and RNAi cocktail also induced apoptosis in Bel‑7402 cells at 72 h following transfection. Reduction of NF‑κB and P53 levels was observed (P<0.05) in Bel‑7402 cells following DR3 silencing, whereas levels of Fas, Caspase3 and Caspase8 were markedly elevated (P<0.05). DR3 expression levels in hepatocellular carcinoma cells were significantly higher than those in normal cells. DR3 silencing effectively inhibited proliferation and invasion of hepatocellular carcinoma cells in vitro. However, silencing of the DR3 gene affect levels of apoptosis antigen‑3 ligand in cells, therefore indicating that it may be involved with other pathways that regulate apoptosis in HCCs. In conclusion, the results of the present study indicated that DR3 may be a promising therapeutic target molecule for further study of hepatocellular carcinoma gene therapy.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
2	Llovet JM and Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 48(Suppl 1): S20–S37. 2008. View Article : Google Scholar : PubMed/NCBI
3	Bergé M, Bonnin P, Sulpice E, et al: Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. Am J Pathol. 177:3192–3201. 2010. View Article : Google Scholar : PubMed/NCBI
4	Schuster MJ and Wu GY: Gene therapy for hepatocellular carcinoma: progress but many stones yet unturned. Gastroenterology. 112:656–659. 1997. View Article : Google Scholar : PubMed/NCBI
5	Chinnaiyan AM, O’Rourke K, Yu GL, et al: Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science. 8:990–992. 1996. View Article : Google Scholar
6	Ashkenazi A and Dixit VM: Death receptor: signaling and modulation. Science. 281:1305–1308. 1998. View Article : Google Scholar : PubMed/NCBI
7	Croft M: The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 9:271–285. 2009. View Article : Google Scholar : PubMed/NCBI
8	Kang YJ, Kim WJ, Bae HU, et al: Involvement of TL1A and DR3 in induction of proinflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. Cytokine. 29:229–235. 2005. View Article : Google Scholar : PubMed/NCBI
9	Fang L, Adkins B, Deyev V and Podack ER: Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J Exp Med. 205:1037–1048. 2008. View Article : Google Scholar : PubMed/NCBI
10	Migone TS, Zhang J, Luo X, et al: TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity. 16:479–492. 2002. View Article : Google Scholar : PubMed/NCBI
11	Pappu BP, Borodovsky A, Zheng TS, et al: TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med. 205:1049–1062. 2008. View Article : Google Scholar : PubMed/NCBI
12	Meylan F, Davidson TS, Kahle E, et al: The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity. 29:79–89. 2008. View Article : Google Scholar : PubMed/NCBI
13	Bamias G, Martin C III, Marini M, et al: Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol. 171:4868–4874. 2003. View Article : Google Scholar : PubMed/NCBI
14	Warzocha K, Ribeiro P, Charlot C, Renard N, Coiffier B and Salles G: A new death receptor 3 isoform: expression in human lymphoid cell lines and non-Hodgkin’s lymphomas. Biochem Biophys Res Commun. 242:376–379. 1998. View Article : Google Scholar : PubMed/NCBI
15	Gout S, Morin C, Houle F and Huot J: Death receptor-3, a new E-Selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation. Cancer Res. 66:9117–9124. 2006. View Article : Google Scholar : PubMed/NCBI
16	Jiang S, Song MJ, Shin EC, Lee MO, Kim SJ and Park JH: Apoptosis in human hepatocarcinoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. Hepatology. 29:101–110. 1999. View Article : Google Scholar
17	Zhang L, Zhang Y, Zhang L, Yang X and Lv Z: Lupeol, a dietary triterpene, inhibited growth and induced apoptosis through down-regulation of DR3 in SMMC7721 cells. Cancer Invest. 27:163–170. 2009. View Article : Google Scholar : PubMed/NCBI
18	Strumberg D: Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc). 41:773–784. 2005. View Article : Google Scholar
19	Adnane L, Trail PA, Taylor I and Wilhelm SM: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 407:597–612. 2006. View Article : Google Scholar : PubMed/NCBI
20	Rini BI: Sorafenib. Expert Opin Pharmacother. 7:453–461. 2006. View Article : Google Scholar : PubMed/NCBI
21	Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 10:145–147. 2004. View Article : Google Scholar : PubMed/NCBI
22	Goodman L: Persistence - luck - Avastin. J Clin Invest. 113:9342004. View Article : Google Scholar
23	Bergsland E and Dickler MN: Maximizing the potential of bevacizumab in cancer treatment. Oncologist. 9(Suppl 1): 36–42. 2004. View Article : Google Scholar : PubMed/NCBI
24	Zhu AX, Blaszkowsky LS, Ryan DP, et al: Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 4:1898–1903. 2006. View Article : Google Scholar
25	David D, Rajappan L, Balachandran KK, et al: Prognostic significance of STAT3 and phosphorylated STAT3 in human soft tissue tumors-a clinicopathological analysis. J Exp Clin Res. 30:562011. View Article : Google Scholar
26	Roth W, Grund K, Wiestler OD and Schirmacher P: The anti-diabetic drug troglitazone sensitizes colon cancer cells to TRAIL-induced apoptosis by down-regulating FLIP. Verh Dtsch Ges Pathol. 91:294–301. 2007.(In German).
27	Zhao B, Li L, Cui K, Wang AL, et al: Mechanisms of TRAIL and gemcitabine induction of pancreatic cancer cell apoptosis. Asian Pac J Cancer Prev. 12:2675–2678. 2011.
28	Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
29	Herold-Mende C, Steiner HH, Andl T, et al: Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab Invest. 79:1573–1582. 1999.
30	Kitson J, Raven T, Jiang YP, et al: A death-domain-containing receptor that mediates apoptosis. Nature. 384:372–375. 1996. View Article : Google Scholar : PubMed/NCBI
31	Marsters SA, Sheridan JP, Donahue CJ, et al: Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Curr Biol. 6:1669–1676. 1996. View Article : Google Scholar : PubMed/NCBI
32	Bodmer JL, Burns K, Schneider P, et al: TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas (Apo-1/CD95). Immunity. 6:79–88. 1997. View Article : Google Scholar : PubMed/NCBI
33	Screaton GR, Xu XN, Olsen AL, Cowper AE, Tan R, McMichael AJ and Bell JI: LARD: A new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. Proc Natl Acad Sci USA. 94:4615–4619. 1997. View Article : Google Scholar : PubMed/NCBI
34	Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 24:4293–4300. 2006. View Article : Google Scholar : PubMed/NCBI
35	Butterfield LH: Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology. 127(5 Suppl 1): S232–S241. 2004. View Article : Google Scholar : PubMed/NCBI
36	Butterfield LH: Recent advances in immunotherapy for hepatocellular cancer. Swiss Med Wkly. 137:83–90. 2007.PubMed/NCBI
37	Song G, Luo Q, Qin J, Wang L, Shi Y and Sun C: Effects of oxymatrine on proliferation and apoptosis in human hepatoma cells. Colloids Surf B Biointerfaces. 48:1–5. 2006. View Article : Google Scholar : PubMed/NCBI
38	Ashkenazi A and Dixit VM: Death receptors: signaling and modulation. Science. 281:1305–1308. 1998. View Article : Google Scholar : PubMed/NCBI
39	Hengartner MO: The biochemistry of apoptosis. Nature. 407:770–776. 2000. View Article : Google Scholar : PubMed/NCBI
40	Nakagawa T, Zhu H, Morishima N, et al: Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature. 403:98–103. 2000. View Article : Google Scholar : PubMed/NCBI
41	Pittoni P, Tripodo C, Piconese S, Mauri G, Parenza M, Rigoni A, Sangaletti S and Colombo MP: Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res. 71:5987–5997. 2011. View Article : Google Scholar : PubMed/NCBI
42	Dechant MJ, Fellenberg J, Scheuerpflug CG, Ewerbeck V and Debatin KM: Mutation analysis of the apoptotic ‘death-receptors’ and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines. Int J Cancer. 109:661–667. 2004. View Article : Google Scholar : PubMed/NCBI
43	He Y, Liu F, Zhang L, et al: Growth inhibition and apoptosis induced by lupeol, a dietary triterpene, in human hepatocellular carcinoma cells. Biol Pharm Bull. 34:517–522. 2011. View Article : Google Scholar : PubMed/NCBI